These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32802733)

  • 1. Comparative Analysis of Immunoactivation by Nanosecond Pulsed Electric Fields and PD-1 Blockade in Murine Hepatocellular Carcinoma.
    Yimingjiang M; Tuergan T; Chen X; Wen H; Shao Y; Zhang R; Aihaiti K; Xue J; Aji T; Zhang W
    Anal Cell Pathol (Amst); 2020; 2020():9582731. PubMed ID: 32802733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response triggered by the ablation of hepatocellular carcinoma with nanosecond pulsed electric field.
    Liu J; Chen X; Zheng S
    Front Med; 2021 Apr; 15(2):170-177. PubMed ID: 33185811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanosecond pulsed electric field (nsPEF) treatment for hepatocellular carcinoma: a novel locoregional ablation decreasing lung metastasis.
    Yin S; Chen X; Hu C; Zhang X; Hu Z; Yu J; Feng X; Jiang K; Ye S; Shen K; Xie H; Zhou L; James Swanson R; Zheng S
    Cancer Lett; 2014 May; 346(2):285-91. PubMed ID: 24462824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
    Voloshin T; Kaynan N; Davidi S; Porat Y; Shteingauz A; Schneiderman RS; Zeevi E; Munster M; Blat R; Tempel Brami C; Cahal S; Itzhaki A; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
    Cancer Immunol Immunother; 2020 Jul; 69(7):1191-1204. PubMed ID: 32144446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8
    Qian J; Chen T; Wu Q; Zhou L; Zhou W; Wu L; Wang S; Lu J; Wang W; Li D; Xie H; Su R; Guo D; Liu Z; He N; Yin S; Zheng S
    Cancer Lett; 2020 Dec; 495():1-11. PubMed ID: 32949680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma.
    Liu S; Yang L; Jia S; Zhao R; Jin Z
    Int Immunopharmacol; 2021 Nov; 100():108161. PubMed ID: 34555643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
    Shigeta K; Datta M; Hato T; Kitahara S; Chen IX; Matsui A; Kikuchi H; Mamessier E; Aoki S; Ramjiawan RR; Ochiai H; Bardeesy N; Huang P; Cobbold M; Zhu AX; Jain RK; Duda DG
    Hepatology; 2020 Apr; 71(4):1247-1261. PubMed ID: 31378984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
    Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
    Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
    Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanosecond pulsed electric field ablation of hepatocellular carcinoma.
    Beebe SJ; Chen X; Liu JA; Schoenbach KH
    Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():6861-5. PubMed ID: 22255915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanosecond pulsed electric field (nsPEF) enhance cytotoxicity of cisplatin to hepatocellular cells by microdomain disruption on plasma membrane.
    Yin S; Chen X; Xie H; Zhou L; Guo D; Xu Y; Wu L; Zheng S
    Exp Cell Res; 2016 Aug; 346(2):233-40. PubMed ID: 27375200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
    Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
    Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
    Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
    J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
    Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.